AUSTIN, Texas - Genprex , Inc. (NASDAQ: NASDAQ:GNPX), a clinical-stage gene therapy company, announced today that the Korean Patent Office has granted a patent for the use of its lead drug candidate, Reqorsa® Immunogene Therapy, with anti-PD-1 and PD-L1 antibodies, extending through 2037. This patent aligns with Genprex's intellectual property strategy, complementing existing patents in other major markets including the U.S., Japan, and China, among others.
The patent pertains to the combination therapy involving Reqorsa and immune checkpoint inhibitors, which are currently being evaluated in Genprex's Acclaim-2 and Acclaim-3 clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), respectively.
Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex, emphasized the importance of securing exclusivity for the drug combinations as the company progresses through clinical trials.
The Acclaim-2 study, which is in Phase 1/2, is testing Reqorsa with Merck & Co (NYSE:MRK).'s Keytruda® in NSCLC patients who have experienced disease progression after Keytruda treatment. Genprex anticipates completing enrollment for the Phase 1 dose escalation portion in the second half of 2024.
The Acclaim-3 study, also in Phase 1/2, involves Reqorsa with Genentech's Tecentriq® as a maintenance therapy for ES-SCLC patients showing tumor progression following initial standard treatment with Tecentriq and chemotherapy. Enrollment for the Phase 1 portion is currently open, with completion expected in the latter half of 2024.
Both Acclaim-2 and Acclaim-3 patient populations have been granted FDA Fast Track Designation, with the Acclaim-3 study also receiving an Orphan Drug Designation.
Genprex's broader mission is to advance gene therapy for cancer and diabetes patients with limited treatment options. Its Oncoprex® Delivery System is designed to deliver genes systemically to fight disease, with Reqorsa being evaluated in clinical trials as a potential treatment for lung cancer. The company is also developing gene therapies for diabetes, aiming to transform pancreatic alpha cells into insulin-producing beta-like cells.
This announcement is based on a press release statement from Genprex, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.